These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 29784744)

  • 1. The Changing Treatment Landscape for Metastatic Urothelial Carcinoma.
    Flaig TW
    J Natl Compr Canc Netw; 2018 May; 16(5S):636-638. PubMed ID: 29784744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent developments in the treatment of advanced bladder cancer.
    Godwin JL; Hoffman-Censits J; Plimack E
    Urol Oncol; 2018 Mar; 36(3):109-114. PubMed ID: 29395952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
    Park JC; Hahn NM
    Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent developments in the management of bladder cancer: Introduction.
    Smith AB
    Urol Oncol; 2018 Mar; 36(3):95-96. PubMed ID: 29158137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma.
    Siefker-Radtke AO; Apolo AB; Bivalacqua TJ; Spiess PE; Black PC
    J Urol; 2018 May; 199(5):1129-1142. PubMed ID: 29113841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of immunotherapy in bladder cancer.
    Rhea LP; Mendez-Marti S; Kim D; Aragon-Ching JB
    Cancer Treat Res Commun; 2021; 26():100296. PubMed ID: 33421822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.
    Koshkin VS; Grivas P
    Curr Oncol Rep; 2018 Apr; 20(6):48. PubMed ID: 29644490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Making urothelial carcinomas less immune to immunotherapy.
    Ramos JD; Yu EY
    Urol Oncol; 2016 Dec; 34(12):534-537. PubMed ID: 27836245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer.
    Giridhar KV; Kohli M
    Mayo Clin Proc; 2017 Oct; 92(10):1564-1582. PubMed ID: 28982487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
    Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
    World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [French ccAFU guidelines – Update 2018–2020: Bladder cancer].
    Rouprêt M; Neuzillet Y; Pignot G; Compérat E; Audenet F; Houédé N; Larré S; Masson-Lecomte A; Colin P; Brunelle S; Xylinas E; Roumiguié M; Méjean A
    Prog Urol; 2019 Sep; 28(S1):R48-R80. PubMed ID: 32093463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging role of checkpoint inhibition in localized bladder cancer.
    Singh P; Black P
    Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a role for maintenance therapy after platinum chemotherapy in bladder cancer in the era of immune therapy?
    Rassy E; Assi T; Kattan J
    Future Oncol; 2019 Dec; 15(34):3877-3879. PubMed ID: 31729240
    [No Abstract]   [Full Text] [Related]  

  • 17. Neoadjuvant PARPi for urothelial carcinoma: between lifeline and desperation.
    Tayeh GA; Alkassis M; Semaan A; Khalil N; Nemr E; Waked C
    Future Oncol; 2021 Sep; 17(25):3281-3283. PubMed ID: 34287018
    [No Abstract]   [Full Text] [Related]  

  • 18. Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review.
    Lavoie JM; Black PC; Eigl BJ
    J Urol; 2019 Jul; 202(1):49-56. PubMed ID: 30730407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Updates in the management and future landscape of urothelial carcinoma.
    Sarkis J; Assaf J
    J Oncol Pharm Pract; 2021 Mar; 27(2):514-515. PubMed ID: 33349147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of immunotherapy in the modern treatment of urothelial carcinoma].
    Maráz A; Géczi L
    Magy Onkol; 2017 Jun; 61(2):139-146. PubMed ID: 28585615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.